(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -4.16% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Amarin's revenue in 2025 is $226,734,000.On average, 5 Wall Street analysts forecast AMRN's revenue for 2025 to be $94,332,248,771, with the lowest AMRN revenue forecast at $87,578,785,008, and the highest AMRN revenue forecast at $103,485,188,268. On average, 5 Wall Street analysts forecast AMRN's revenue for 2026 to be $85,216,736,106, with the lowest AMRN revenue forecast at $66,386,881,475, and the highest AMRN revenue forecast at $110,471,530,092.
In 2027, AMRN is forecast to generate $84,393,345,819 in revenue, with the lowest revenue forecast at $61,941,405,636 and the highest revenue forecast at $110,034,883,728.